Discover the most recent news about our Company.
Biosfer Teslab at the International Conference on Genomic Medicine 2022 We only know what we know… We have to continue
Abstract Background and aims: Inflammation is a pathophysiological mechanism of atherosclerosis, and several mediators have been proposed as biomarkers. Acute-phase serum
Abstract Preeclampsia (PE) and fetal growth restriction (FGR) are both placenta-mediated disorders with unclear pathogenesis. Metabolomics of maternal and fetal
Annual Scientific Meeting of CIBERDEM The Consorcio Centro de Investigación Biomédica en Red (CIBER) which depends on the Instituto de
Elite controllers (ECs) are an exceptional group of people living with HIV (PLWH) who maintain undetectable viral loads (VLs) despite
Background: Heart failure with preserved ejection fraction (HFpEF) is a disorder related to patient comorbidities and aging. Whether mitochondrial dysfunction is
The role of inflammation in heart failure (HF) has been extensively described, but it is uncertain whether inflammation exerts a
Abstract Objective: Vascular aging (arterial stiffness [AS]) is an inflammation-linked process that predicts macro- and microvascular complications in adults with type
Biosfer Teslab desenvolupa el Test MetBalance: una innovadora anàlisi de sang per a monitoritzar la salut metabòlica i revolucionar la
Biosfer Teslab develops MetBalance Test: an innovative blood test to monitor metabolic health and revolutionize the way you take care
Objective chronic inflammation and immune dysregulation are crucial mechanisms for atherosclerosis in rheumatoid arthritis (RA). Recent evidence suggests a link
Biosfer Teslab again in Circulation Biosfer Teslab’s R&D activity is continuous, not only in terms of optimisation and development of
